 | Up a level |
Hovaguimian, F; Martin, E; Reinacher, M; Rasi, M; Schmidt, A J; Bernasconi, E; El Amari, E B; Braun, D L; Calmy, A; Darling, K; Christinet, V; Depmeier, C; Hauser, C; Läuchli, S; Notter, J; Stoeckle, M; Surial, B; Vernazza, P; Bruggmann, P; Tarr, P; ... (2022). Participation, retention and uptake in a multicentre pre-exposure prophylaxis cohort using online, smartphone-compatible data collection. HIV medicine, 23(2), pp. 146-158. Wiley 10.1111/hiv.13175
Reichmuth, M L; Chaudron, S E; Bachmann, N; Nguyen, H; Böni, J; Metzner, K J; Perreau, M; Klimkait, T; Yerly, S; Hirsch, H H; Hauser, C; Ramette, A; Vernazza, P; Cavassini, M; Bernasconi, E; Günthard, H F; Kusejko, K; Kouyos, R D (2021). Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission. HIV medicine, 22(5), pp. 346-359. Wiley 10.1111/hiv.13030
Vernazza, P; Tschudin, S; Kronenberg, Andreas Oskar; Hauser, Christoph Victor; Huttner, B; Manuel, O; Kuster, S; Scheidegger, C; Berger, C; Müller, N (2018). Entwicklung infektiologischer Guidelines – ein kontinuierlicher Prozess. Swiss Medical Forum, 18(46), pp. 963-965. EMH Swiss Medical Publishers 10.4414/smf.2018.03382
Hasse, Barbara; Tarr, Philip E; Marques-Vidal, Pedro; Waeber, Gerard; Preisig, Martin; Mooser, Vincent; Valeri, Fabio; Djalali, Sima; Rauch, Andri; Bernasconi, Enos; Calmy, Alexandra; Cavassini, Matthias; Vernazza, Pietro; Battegay, Manuel; Weber, Rainer; Senn, Oliver; Vollenweider, Peter; Ledergerber, Bruno; Aubert, V; Barth, J; ... (2015). Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. Open Forum Infectious Diseases, 2(3), ofv108. Oxford University Press 10.1093/ofid/ofv108
Kouyos, Roger D; Hasse, Barbara; Calmy, Alexandra; Cavassini, Matthias; Furrer, Hansjakob; Stöckle, Marcel; Vernazza, Pietro L; Bernasconi, Enos; Weber, Rainer; Günthard, Huldrych F; Aubert, V; Battegay, M; Bernasconi, E; Böni, J; Bucher, H C; Burton-Jeangros, C; Calmy, A; Cavassini, M; Dollenmaier, G; Egger, M; ... (2015). Increases in Condomless Sex in the Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2(2), ofv077. Oxford University Press 10.1093/ofid/ofv077
Magenta, L; Dell-Kuster, S; Richter, W O; Young, J; Hasse, B; Flepp, M; Hirschel, B; Vernazza, P; Evison, J; Cavassini, M; Decosterd, L A; Bucher, H C; Bernasconi, E; Swiss HIV Cohort Study (SHCS), (2011). Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy. AIDS research and human retroviruses, 27(5), pp. 525-33. New York, N.Y.: Mary Ann Liebert 10.1089/aid.2010.0207
Ledergerber, B; Cavassini, M; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B; Furrer, H; Rickenbach, M; Weber, R; Swiss HIV Cohort Study (SHCS), (2011). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV medicine, 12(5), pp. 279-88. Oxford: Blackwell Science 10.1111/j.1468-1293.2010.00880.x
Young, J; Scherrer, A U; Günthard, Hf; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, Ca; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, Hc; Swiss HIV Cohort Study, (2011). Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV medicine, 12(5), pp. 299-307. Oxford: Blackwell Science 10.1111/j.1468-1293.2010.00885.x
El Amari, E Boffi; Combescure, C; Yerly, S; Calmy, A; Kaiser, L; Hasse, B; Furrer, H; Cavassini, M; Vernazza, P; Hirsch, Hh; Bernasconi, E; Hirschel, B; Swiss HIV Cohort Study, (2011). Clinical relevance of cytomegalovirus viraemia(*,†). HIV medicine, 12(7), pp. 394-402. Oxford: Blackwell Science 10.1111/j.1468-1293.2010.00900.x
Bucher, HC; Richter, W; Glass, TR; Magenta, L; Wang, Q; Cavassini, M; Vernazza, P; Hirschel, B; Weber, R; Furrer, H; Battegay, M; Bernasconi, E (2011). Small dense lipoproteins, apolipoprotein B and risk of coronary events in HIV-infected patients on antiretroviral therapy. Journal of acquired immune deficiency syndromes JAIDS, 60(2), pp. 135-142. Philadelphia, Pa.: Lippincott Williams & Wilkins 10.1097/QAI.0b013e31824476e1
Bellini, C; Keiser, O; Chave, J-P; Evison, Jm; Fehr, J; Kaiser, L; Weber, R; Vernazza, P; Bernasconi, E; Telenti, A; Cavassini, M (2009). Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV medicine, 10(1), pp. 12-18. Oxford: Blackwell Science 10.1111/j.1468-1293.2008.00646.x
Combescure, Christophe; Vallier, N; Ledergerber, B; Cavassini, M; Furrer, H; Rauch, A; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B (2009). How reliable is an undetectable viral load? HIV medicine, 10(8), pp. 470-6. Oxford: Blackwell Science 10.1111/j.1468-1293.2009.00714.x
Fux, CA; Simcock, M; Wolbers, M; Bucher, HC; Hirschel, B; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H; Swiss, HIV Cohort Study (2007). Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antiviral therapy, 12(8), pp. 1165-73. London: International Medical Press
Wolbers, M; Opravil, M; von Wyl, V; Hirschel, B; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Battegay, M; Yerly, S; Günthard, H; Bucher, HC; Swiss, HIV Cohort Study (2007). Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS, 21(16), pp. 2201-7. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/QAD.0b013e3282efacb1
Simcock, M; Blasko, M; Karrer, U; Bertisch, B; Pless, M; Blumer, L; Vora, S; Robinson, JO; Bernasconi, E; Terziroli, B; Moirandat-Rytz, S; Furrer, H; Hirschel, B; Vernazza, P; Sendi, P; Rickenbach, M; Bucher, HC; Battegay, M; Koller, MT and Swiss, HIV Cohort Study (2007). Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antiviral therapy, 12(6), pp. 931-9. London: International Medical Press
Arnedo, M; Taffé, P; Sahli, R; Furrer, H; Hirschel, B; Elzi, L; Weber, R; Vernazza, P; Bernasconi, E; Darioli, R; Bergmann, S; Beckmann, JS; Telenti, A; Tarr, PE; Swiss, HIV Cohort Study (2007). Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenetics and genomics, 17(9), pp. 755-64. London: Lippincott Williams & Wilkins 10.1097/FPC.0b013e32814db8b7
Ananworanich, J; Gayet-Ageron, A; Le Braz, M; Prasithsirikul, W; Chetchotisakd, P; Kiertiburanakul, S; Munsakul, W; Raksakulkarn, P; Tansuphasawasdikul, S; Sirivichayakul, S; Cavassini, M; Karrer, U; Genné, D; Nüesch, R; Vernazza, P; Bernasconi, E; Leduc, D; Satchell, C; Yerly, S; Perrin, L; ... (2006). CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet, 368(9534), pp. 459-65. London: Elsevier 10.1016/S0140-6736(06)69153-8
Müller, V; Ledergerber, B; Perrin, L; Klimkait, T; Furrer, H; Telenti, A; Bernasconi, E; Vernazza, P; Günthard, HF; Bonhoeffer, S; Swiss, HIV Cohort Study (2006). Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS, 20(6), pp. 889-94. Hagerstown, Md.: Lippincott Williams & Wilkins
Schüpbach, J; Günthard, H; Joos, B; Fischer, M; Böni, J; Tomasik, Z; Yerly, S; Perrin, L; Battegay, M; Furrer, H; Vernazza, P; Bernasconi, E; Hirschel, B; Swiss, HIV Cohort Study (2005). HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. Journal of acquired immune deficiency syndromes JAIDS, 40(3), pp. 250-6. Philadelphia, Pa.: Lippincott Williams & Wilkins
Rotger, M; Taffe, P; Bleiber, G; Gunthard, HF; Furrer, H; Vernazza, P; Drechsler, H; Bernasconi, E; Rickenbach, M; Telenti, A; Swiss, HIV Cohort Study (2005). Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. Journal of infectious diseases, 192(8), pp. 1381-6. Cary, N.C.: The University of Chicago Press 10.1086/466531
Young, J; Weber, R; Rickenbach, M; Furrer, H; Bernasconi, E; Hirschel, B; Tarr, PE; Vernazza, P; Battegay, M; Bucher, HC (2005). Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antiviral therapy, 10(5), pp. 585-91. London: International Medical Press
Rauch, A; Rickenbach, M; Weber, R; Hirschel, B; Tarr, PE; Bucher, HC; Vernazza, P; Bernasconi, E; Zinkernagel, AS; Evison, J; Furrer, H; Swiss, HIV Cohort Study (2005). Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clinical infectious diseases, 41(3), pp. 395-402. Cary, N.C.: The University of Chicago Press 10.1086/431486
Kaufmann, GR; Furrer, H; Ledergerber, B; Perrin, L; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Rickenbach, M; Hirschel, B; Battegay, M; Swiss, HIV Cohort Study (2005). Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clinical infectious diseases, 41(3), pp. 361-72. Cary, N.C.: The University of Chicago Press 10.1086/431484
Tarr, PE; Taffé, P; Bleiber, G; Furrer, H; Rotger, M; Martinez, R; Hirschel, B; Battegay, M; Weber, R; Vernazza, P; Bernasconi, E; Darioli, R; Rickenbach, M; Ledergerber, B; Telenti, A; Swiss, HIV Cohort Study (2005). Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. Journal of infectious diseases, 191(9), pp. 1419-26. Cary, N.C.: The University of Chicago Press 10.1086/429295
Young, J; Rickenbach, M; Weber, R; Furrer, H; Bernasconi, E; Hirschel, B; Tarr, PE; Vernazza, P; Battegay, M; Bucher, HC (2005). Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antiviral therapy, 10(1), pp. 73-81. London: International Medical Press
